Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapies for endocrine and metabolic disorders [5] - The company utilizes its proprietary PEP™ platform to advance a pipeline of candidates targeting significant unmet medical needs with large market opportunities [5] Public Offering Details - MBX Biosciences announced the pricing of its upsized public offering of 11,108,055 shares at a price of $18.00 per share, expecting gross proceeds of approximately $199.9 million before deductions [1] - The offering includes a 30-day option for underwriters to purchase an additional 1,666,208 shares at the public offering price [1] - The offering is expected to close on September 26, 2025, pending customary closing conditions [1] Underwriters - J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering [2] - Citizens Capital Markets and Oppenheimer & Co. are serving as co-lead managers [2] Regulatory Compliance - A registration statement for the offering was filed with the Securities and Exchange Commission and declared effective on September 24, 2025 [3] - The offering is being conducted solely through a prospectus [3]
MBX Biosciences Announces Pricing of Upsized Public Offering